Literature DB >> 6968038

Involvement of the B-lymphoid system in chronic myelogenous leukaemia.

P J Martin, V Najfeld, J A Hansen, G K Penfold, R J Jacobson, P J Fialkow.   

Abstract

Studies with glucose-6-phosphate dehydrogenase (G6PD) isoenzymes have demonstrated that chronic myelogenous leukaemia (CML) is a clonal disorder of pluripotent haematopoietic stem cells which are capable of differentiation to myeloid cells, monocytes, erthrocytes and platelets. It has been observed recently in G6PD heterozygous patients with chronic phase CML that the non-E-rosetting lymphocytes were restricted to a single enzyme type, indicating that some lymphoid cells must also arise from the leukaemic clone. Surface or cytoplasmic immunoglobulin could be detected in up to 46% of the cells of these isolated non-T-lymphocyte populations, which suggested that cells from the CML clone were capable of differentiating into B lymphocytes. To investigate this further, we established Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cell lines derived from patients with CML and studied chromosomes and G6PD to determine whether progenitor B lymphocytes for any of the cell lines had originated from the CML clone. We report here direct evidence that immunoglobulin-synthesizing B lymphocytes can arise from the CML stem cell clone.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968038     DOI: 10.1038/287049a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  23 in total

1.  Therapeutic workshop on modifying the disease process in rheumatoid arthritis: immunosuppression in perspective.

Authors: 
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

2.  Familial leukemia: Ph1 positive acute lymphoid leukemia of a mother and her infant.

Authors:  E Oláh; V Stenszky; A Kiss; I Kovács; E Balogh; L Karmazsin
Journal:  Blut       Date:  1981-10

3.  Specificity of monoclonal anti-K 562 antibody.

Authors:  H W Schienle; W Müller-Ruchholtz
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

Review 4.  A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F).

Authors:  Ayalew Tefferi
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

Review 5.  Leukemia stem cells: Old concepts and new perspectives.

Authors:  Samanta A Mariani; Bruno Calabretta
Journal:  Mol Aspects Med       Date:  2013-06-29

6.  Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells.

Authors:  Tom Lenaerts; Jorge M Pacheco; Arne Traulsen; David Dingli
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

7.  A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.

Authors:  E Freed; T Hunter
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

Review 8.  Human chromosome 22.

Authors:  J C Kaplan; A Aurias; C Julier; M Prieur; M F Szajnert
Journal:  J Med Genet       Date:  1987-02       Impact factor: 6.318

Review 9.  Benign hematopoietic progenitors in chronic myeloid leukemia: current status and future prospects.

Authors:  F Cervantes; C Rozman
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

10.  A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition.

Authors:  Daniel J Goff; Angela Court Recart; Anil Sadarangani; Hye-Jung Chun; Christian L Barrett; Maryla Krajewska; Heather Leu; Janine Low-Marchelli; Wenxue Ma; Alice Y Shih; Jun Wei; Dayong Zhai; Ifat Geron; Minya Pu; Lei Bao; Ryan Chuang; Larisa Balaian; Jason Gotlib; Mark Minden; Giovanni Martinelli; Jessica Rusert; Kim-Hien Dao; Kamran Shazand; Peggy Wentworth; Kristen M Smith; Christina A M Jamieson; Sheldon R Morris; Karen Messer; Lawrence S B Goldstein; Thomas J Hudson; Marco Marra; Kelly A Frazer; Maurizio Pellecchia; John C Reed; Catriona H M Jamieson
Journal:  Cell Stem Cell       Date:  2013-01-17       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.